The recently launched Scenaria View Focus Edition computed tomography (CT) system features an advanced cardiac motion correction tool that reportedly provides significantly higher temporal resolution than conventional image reconstruction.
Fujifilm Healthcare Americas Corporation has launched the Scenaria View Focus Edition computed tomography (CT) system, a device that may enhance cardiac imaging and reportedly reduces radiation dosing by up to 83 percent.
The Scenaria View Focus Edition, which received 510(k) clearance from the Food and Drug Administration (FDA) in April 2022, may be utilized for a variety of routine and advanced applications, including dual energy exams, interventional radiology procedures and coronary computed tomography angiography (CCTA), according to the company. The new CT system will be showcased at the upcoming Radiological Society of North America (RSNA) annual meeting November 27 to December 1 in Chicago.
Fujifilm said a unique feature of the Scenaria View Focus Edition CT system is the Cardio StillShot, a cardiac motion correction tool, which captures two data sets in each scan that are subsequently compared to help detect and correct heart motion. The Cardio StillShot allows temporal resolution of 28 milliseconds with final images in comparison to 175 milliseconds with conventional image reconstruction, according to Fujifilm.
In comparison to conventional filtered back projection image reconstruction, Fujifilm said the Scenaria View Focus Edition’s use of iterative reconstruction reduces radiation dosing by up to 83 percent and reduces image noise by up to 90 percent.
“Providers need a powerful CT system that gives them the diagnostic confidence to make the right treatment decisions for their patients,” noted Mark Silverman, the director of marketing for CT at Fujifilm Healthcare Americas Corporation. “Fujifilm’s Scenaria View Focus Edition makes this possible through the convergence of high temporal resolution, enhanced workflow that reduces examination time, and advanced dose reduction capabilities.”
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.